Dual probe difference specimen imaging for prostate cancer margin assessment

Abstract. Significance Positive margin status due to incomplete removal of tumor tissue during radical prostatectomy for high-risk localized prostate cancer requires reoperation or adjuvant therapy, which increases morbidity and mortality. Adverse effects of prostate cancer treatments commonly include erectile dysfunction, urinary incontinence, and bowel dysfunction, making successful initial curative prostatectomy imperative. Aim Current intraoperative tumor margin assessment is largely limited to frozen section analysis, which is a lengthy, labor-intensive process that is obtrusive to the clinical workflow within the operating room (OR). Therefore, a rapid method for prostate cancer margin assessment in the OR could improve outcomes for patients. Approach Dual probe difference specimen imaging (DDSI), which uses paired antibody-based probes that are labeled with spectrally distinct fluorophores, was shown herein for prostate cancer margin assessment. The paired antibody-based probes consisted of a targeted probe to prostate-specific membrane antigen (PSMA) and an untargeted probe, which were used as a cocktail to stain resected murine tissue specimens including prostate tumor, adipose, muscle, and normal prostate. Ratiometric images (i.e., DDSI) of the difference between targeted and untargeted probe uptake were calculated and evaluated for accuracy using receiver operator characteristic curve analysis with area under the curve values used to evaluate the utility of the DDSI method to detect PSMA positive prostate cancer. Results Targeted and untargeted probe uptake was similar between the high and low PSMA expressing tumor due to nonspecific probe uptake after topical administration. The ratiometric DDSI approach showed substantial contrast difference between the PSMA positive tumors and their respective normal tissues (prostate, adipose, muscle). Furthermore, DDSI showed substantial contrast difference between the high PSMA expressing tumors and the minimally PSMA expressing tumors due to the ratiometric correction for the nonspecific uptake patterns in resected tissues. Conclusions Previous work has shown that ratiometic imaging has strong predictive value for breast cancer margin status using topical administration. Translation of the ratiometric DDSI methodology herein from breast to prostate cancers demonstrates it as a robust, ratiometric technique that provides a molecularly specific imaging modality for intraoperative margin detection. Using the validated DDSI protocol on resected prostate cancers permitted rapid and accurate assessment of PSMA status as a surrogate for prostate cancer margin status. Future studies will further evaluate the utility of this technology to quantitatively characterize prostate margin status using PSMA as a biomarker.

[1]  H. Leung,et al.  Raman Spectroscopy in Prostate Cancer: Techniques, Applications and Advancements , 2022, Cancers.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  Connor W. Barth,et al.  Clinically relevant dual probe difference specimen imaging (DDSI) protocol for freshly resected breast cancer specimen staining , 2021, BMC cancer.

[4]  Connor W. Barth,et al.  Topical dual-probe staining using quantum dot-labeled antibodies for identifying tumor biomarkers in fresh specimens , 2020, PloS one.

[5]  Connor W. Barth,et al.  Fluorescence image-guided surgery: a perspective on contrast agent development , 2020, BiOS.

[6]  Sunil Singhal,et al.  Review of clinical trials in intraoperative molecular imaging during cancer surgery , 2019, Journal of biomedical optics.

[7]  Ahmedin Jemal,et al.  Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[8]  Pieterjan Debie,et al.  Latest developments in molecular tracers for fluorescence image-guided cancer surgery. , 2019, The Lancet. Oncology.

[9]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[10]  Scott C Davis,et al.  Diagnostic performance of receptor-specific surgical specimen staining correlates with receptor expression level , 2019, Journal of biomedical optics.

[11]  D. Byrd,et al.  Real-time Visualization of Breast Carcinoma in Pathology Specimens From Patients Receiving Fluorescent Tumor-Marking Agent Tozuleristide. , 2018, Archives of pathology & laboratory medicine.

[12]  Sunil Singhal,et al.  Evaluation of Novel Tumor-Targeted Near-Infrared Probe for Fluorescence-Guided Surgery of Cancer. , 2018, Journal of medicinal chemistry.

[13]  Sally M Hull,et al.  Optimizing Glioma Detection Using an EGFR‐Targeted Fluorescent Affibody , 2018, Photochemistry and photobiology.

[14]  Thomas D. Wang,et al.  Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications , 2018, Contrast media & molecular imaging.

[15]  Alexander L. Vahrmeijer,et al.  Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent , 2018, Annals of Surgical Oncology.

[16]  Guolan Lu,et al.  Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence. , 2018, Cancer research.

[17]  Travis L. Rice-Stitt,et al.  Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system , 2018, Breast Cancer Research and Treatment.

[18]  Johan F. Langenhuijsen,et al.  Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study , 2018, Theranostics.

[19]  B. Pogue,et al.  Application of Fluorescence-Guided Surgery to Subsurface Cancers Requiring Wide Local Excision , 2018, Cancer control : journal of the Moffitt Cancer Center.

[20]  J. Benson,et al.  Novel techniques for intraoperative assessment of margin involvement , 2018, Ecancermedicalscience.

[21]  Zachary T. Harmany,et al.  Microscopy with ultraviolet surface excitation for rapid slide-free histology , 2017, Nature Biomedical Engineering.

[22]  Scott C. Davis,et al.  Optimizing fresh specimen staining for rapid identification of tumor biomarkers during surgery , 2017, Theranostics.

[23]  Keith Paulsen,et al.  Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use , 2017, Molecular Imaging and Biology.

[24]  A. Harootunian,et al.  Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study , 2017, Annals of Surgical Oncology.

[25]  Alexander L Vahrmeijer,et al.  SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery. , 2017, Surgical oncology.

[26]  W. Stummer,et al.  Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas , 2017, Neurosurgery.

[27]  Vasilis Ntziachristos,et al.  Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study , 2016, Clinical Cancer Research.

[28]  Jonathan T. C. Liu,et al.  Multiplexed Molecular Imaging of Biomarker-Targeted SERS Nanoparticles on Fresh Tissue Specimens with Channel-Compressed Spectrometry , 2016, PloS one.

[29]  J. Olson,et al.  Fluorescence Identification of Head and Neck Squamous Cell Carcinoma and High-Risk Oral Dysplasia With BLZ-100, a Chlorotoxin-Indocyanine Green Conjugate. , 2016, JAMA otolaryngology-- head & neck surgery.

[30]  Jonathan T. C. Liu,et al.  Surgical Guidance via Multiplexed Molecular Imaging of Fresh Tissues Labeled With SERS-Coded Nanoparticles , 2016, IEEE Journal of Selected Topics in Quantum Electronics.

[31]  P. Low,et al.  Intraoperative Molecular Diagnostic Imaging Can Identify Renal Cell Carcinoma. , 2016, The Journal of urology.

[32]  Jonathan T. C. Liu,et al.  Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent , 2016, Scientific Reports.

[33]  Milind Rajadhyaksha,et al.  Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy , 2016, Scientific Reports.

[34]  Jeffrey K. Mito,et al.  A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer , 2016, Science Translational Medicine.

[35]  Connor W. Barth,et al.  Polymeric Micelles as Carriers for Nerve-Highlighting Fluorescent Probe Delivery , 2015, Molecular pharmaceutics.

[36]  T. Poeppel,et al.  PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status , 2015, Theranostics.

[37]  Yu Winston Wang,et al.  In vivo multiplexed molecular imaging of esophageal cancer via spectral endoscopy of topically applied SERS nanoparticles. , 2015, Biomedical optics express.

[38]  Jinzuo Ye,et al.  Intraoperative Imaging-Guided Cancer Surgery: From Current Fluorescence Molecular Imaging Methods to Future Multi-Modality Imaging Technology , 2014, Theranostics.

[39]  W. Oyen,et al.  Targeted Radionuclide and Fluorescence Dual-modality Imaging of Cancer: Preclinical Advances and Clinical Translation , 2014, Molecular Imaging and Biology.

[40]  Scott C Davis,et al.  Topical dual-stain difference imaging for rapid intra-operative tumor identification in fresh specimens. , 2013, Optics letters.

[41]  Summer L. Gibbs,et al.  Near infrared fluorescence for image-guided surgery. , 2012, Quantitative imaging in medicine and surgery.

[42]  T. Church,et al.  Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  H. Ananias,et al.  Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer , 2009, The Prostate.

[44]  G. Sauter,et al.  Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure. , 2009, European urology.

[45]  Slave Trajanoski,et al.  Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.

[46]  R. Knuechel,et al.  Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid--first clinical experiences. , 2008, Urology.

[47]  Zhenghong Lee,et al.  Targeted treatment of prostate cancer , 2007, Journal of cellular biochemistry.

[48]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[49]  M. Lein,et al.  Photodynamic Therapy of Prostate Cancer by Means of 5-Aminolevulinic Acid-Induced Protoporphyrin IX – In vivo Experiments on the Dunning Rat Tumor Model , 2004, Urologia Internationalis.

[50]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  R. Zarbo,et al.  Interinstitutional comparison of frozen section turnaround time. A College of American Pathologists Q-Probes study of 32868 frozen sections in 700 hospitals. , 1997, Archives of pathology & laboratory medicine.

[52]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[53]  A. Deblasio,et al.  Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. , 1994, Cancer research.

[54]  John Y. K. Lee,et al.  Folate Receptor Near-Infrared Optical Imaging Provides Sensitive and Specific Intraoperative Visualization of Nonfunctional Pituitary Adenomas. , 2019, Operative neurosurgery.

[55]  M. Sadelain,et al.  A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? , 2001, Critical reviews in immunology.

[56]  J. Lynch Treatment of advanced prostate cancer. , 1993, The Journal of family practice.

[57]  G. Murphy,et al.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.